Yes, we could have up to 60 centres across US and Europe. The majority will be done through Clevland but as long as at least one is done in other centres (often where our Ad Board members work) they can then potentially (if we get approval) continue to use the valve if they and the patient wish.
I would expect the income to be the same as what we get reimbursed for the trial.
Ann: Data Update on First-in-Human Study of DurAVR at NY Valves, page-12
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.25 |
Change
-0.250(1.61%) |
Mkt cap ! $322.3M | |||
| Open | High | Low | Value | Volume |
| $15.50 | $15.50 | $14.80 | $140.4K | 9.315K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 297 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.25 | 1300 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |